ARCHIMED Acquires Majority Stake in Arkstone
ARCHIMED has acquired a majority stake in Arkstone Medical Solutions, a biotechnology company known for its AI-driven clinical decision support systems. This acquisition, announced in a press release, aims to enhance Arkstone's global reach and accelerate its research and development capabilities.
Arkstone's flagship product, the OneChoice Report, utilizes machine learning and AI to provide precise infectious disease treatment recommendations by analyzing laboratory results and patient data. This tool is already in use across various laboratories in the United States and internationally, transforming how healthcare providers diagnose and treat infectious diseases.
With ARCHIMED's investment and expertise, Arkstone plans to expand its market presence and further develop its products to combat antimicrobial resistance, a significant public health challenge. The acquisition will allow Arkstone to continue operating with its existing team while focusing on rapid growth and innovation.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Sep 22 Ande Raises More Than $52 Million for Corporate Entertainment Platform Sep 22 xtraCHEF Founders Launch Tandem for Restaurant Operations Sep 22 Nexstrom Raises $12 Million for 12 Inch Semiconductor Wafer Platform Sep 22 Sela AI Raises $21 Million for Mortgage Voice Agents Sep 22 Baselayer Raises $35 Million and Launches Identity Suite for AI AgentsMore from Life Sciences
Sep 22 Aqurio Named Finalist for 2026 AI Startup of the Year Sep 22 Tsingke Introduces Validation Workflow for AI Designed Proteins Sep 22 QC Healthcare Partners With Sanguina for AI Blood Health Screening Sep 22 RIVANNA Files 100th Patent for Ultrasound AI Sep 22 Ultima Genomics Platform Selected for Precure's One Million Sample DatasetLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Atman Health Wins ARPA-H Award to Build Heart Failure AI
Imagenet Acquires Analytica Consulting for Data Analytics and AI
ARPA-H Awards UpDoc Up to $9.2 Million for Clinical AI
Medtronic to Invest About $700 Million in Cornerstone Robotics
I-care Acquires Amiral Technologies for Predictive Maintenance AI
Daily AI Brief: the AI news that matters, in your inbox.